Palvella Therapeutics Stock
Palvella Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Wesley H. Kaupinen
- Employees
- 29
- Market cap
- $1.7 B
- IPO
- 02/01/2015
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, USA. The company is dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Palvella Therapeutics stock: price history
1D
-5.5%
1W
-13.3%
1M
-20.6%
6M
-7.5%
YTD
+14.9%
1Y
+64.5%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~23% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Palvella Therapeutics
Analyst assessment of Palvella Therapeutics
PRICE TARGET LOW
US$207.00
CONSENSUS
US$228.50
MEDIAN
US$229.00
PRICE TARGET HIGH
US$246.00
1
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 12/10/2026
Palvella Therapeutics stock metrics
P/E
-24.91
P/B
7.96
EV/EBITDA
-30.92
RETURN ON EQUITY
-10.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.4%
FLOAT SHARES
9,135,127
AVG. DAILY VOLUME (30D)
229,696
Insider transactions (SEC)
JENKINS GEORGE M
JENKINS GEORGE M
JENKINS GEORGE M
JENKINS GEORGE M
JENKINS GEORGE M
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Palvella Therapeutics stock
What does Palvella Therapeutics do?
Palvella Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Wesley H. Kaupinen, the company employs around 29 people.
The IPO was on 02/01/2015; the stock trades on NASDAQ under the ticker PVLA.
What do analysts say about Palvella Therapeutics stock?
11 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$228.50, ranging from US$207.00 to US$246.00, with a median of US$229.00.
This is an external assessment, not a statement by Market Jury.
When does Palvella Therapeutics report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 23% stronger than usual.
Does Palvella Therapeutics pay a dividend?
No, Palvella Therapeutics currently does not pay a dividend.
Which stocks are comparable to Palvella Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Palvella Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Palvella Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.